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Abstract
Background: Chronic heart failure (CHF) is an important epidemiological and therapeuthic issue 
with poor prognosis. The aim of the study was to estimate the prognostic value of daytime heart rate 
(HR), blood pressure (BP), their products and quotients in patients with CHF.
Methods: The study included 80 stable patients with CHF and reduced left ventricular ejection frac-
tion (LVEF ≤ 35%). Physical examination, laboratory blood tests, electrocardiogram, chest X-ray, 
echocardiography, 6-minute walk test, telemetry monitoring and BP measurements were performed 
in all participants. We estimated mean daytime: BP, HR, their products and quotients. The follow-up 
period was 6 months. Major adverse cardiac events (MACE) included: death, cardiovascular death, 
hospitalization due to CHF exacerbation.
Results: The analysis involved all recruited patients with CHF (91% men) aged 59 ± 12 years, in New 
York Heart Association class 2.15 ± 0.57 and reduced LVEF (mean LVEF: 23 ± 6%). The 3-month 
and 6-month mortality rates were 4% and 6%, respectively. There was a significant correlation between 
diastolic blood pressure (DBP), all-cause mortality (p = 0.048) and CHF decompensation (p = 0.0004) 
after 3-month observation period. No relationship was found between HR or systolic blood pressure 
(SBP) and MACE. Both higher SBP × HR and DBP × HR products were related to lower risk of heart 
failure exacerbations during 6-month follow-up. None of the analyzed products or ratios had an impact 
on mortality in this study group. 
Conclusions: Diastolic blood pressure, SBP × HR and DBP × HR products may be useful in sub-
sequent heart failure exacerbation risk stratification. Moreover, DBP value may predict short-term 
mortality in patients with CHF. (Cardiol J 2019; 26, 1: 20–28)
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Introduction
The management of patients suffering from 
chronic heart failure (CHF) is one of the most 
challenging issues in cardiology today. Due to the 
ageing of world populations, advances in acute 
coronary syndrome treatment and effective sec-
ondary prevention, the prevalence of CHF in-
creases systematically [1]. The incidence of CHF is 
particularly high in elderly people. More than 50% 
of patients with new onset HF is ≥ 75 years old [2]. 
Despite improvements in pharmacological and 
invasive therapy of HF the prognosis still remains 
poor. There are many risk factors leading to HF 
development and progression [1]. Nevertheless, 
the search for biomarkers and factors are useful 
in CHF outcome prediction not only to be able to 
stratify the risk but also to improve quality of life, 
decrease the number of subsequent hospitaliza-
tions and mortality rates [3].
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Hypertension (HTN) is a most important 
cardiovascular risk factor and apart from stroke, 
heart failure (HF) is one of the most frequent com-
plications of HTN [1]. Optimal blood pressure (BP) 
control in hypertensive patients may significantly 
delay HF onset and is possible using pharmaco-
logical and non-pharmacological treatment. Un-
fortunatelly, the rate of successful implementation 
of non-pharmacological treatment is low even in 
patients with diagnosed HTN [1, 4]. Conversely to 
the general population, patients with CHF usually 
do not benefit from intensive antihypertensive 
therapy [5–7]. As a result of standard pharmaco-
therapy including angiotensin converting enzyme 
(ACE) inhibitors or angiotensin receptors blockers 
(ARB), beta-blockers, mineralocorticoid receptors 
antagonists (MRA) and diuretics, the majority of 
patients with HF and reduced left ventricular ejec-
tion fraction (HFrEF) have low or even very low BP 
values. Moreover, the phenomenon of the J-shaped 
mortality curve in the other group of patients with 
cardiovascular diseases was observed, which may 
also be apparent in the HF population. SPRINT Re-
search Group revealed that among patients at high 
risk for cardiovascular events but without diabetes, 
targeting  systolic blood pressure (SBP) of less than 
120 mmHg, as compared with less than 140 mmHg, 
resulted in lower rates of fatal and nonfatal major 
cardiovascular events and death from any cause. 
Nevertheless, significantly higher rates of some 
adverse events were observed in the intensive-
treatment group [8]. Bavishi et al. [9] observed 
that in older hypertensive patients, intensive BP 
control decreased cardiovascular mortality and HF, 
although they had increased risk of renal failure. 
One of the most difficult challenges in the treatment 
of patients with CHF are recurrent exacerbations of 
this disease. Prior hospitalization is one of the im-
portant risk factors predicting subsequent episodes 
of CHF decompensation [10]. The relationship 
between BP and risk for CHF decompensation has 
not been clearly established. Thus, the influence 
of BP on prognosis of patients with CHF remains 
uncertain and requires additional studies.
Heart rate (HR) is an independent cardiovas-
cular risk factor in the general population [11]. 
Data from many trials demonstrated relationship 
between increased resting HR and mortality in the 
majority of cardiovascular diseases [12, 13]. Other 
studies have confirmed the positive role of HR in 
lowering cardiac event prevention. Heart failure 
involves many compensation mechanisms leading 
to an HR increase. Many authors have observed 
the correlation between increased HR and higher 
risk of major adverse cardiac events (MACE) in 
patients with CHF [1, 14]. Nevertheless, its role 
in HF needs further investigation.
Double product (DP), defined as HR multiplied 
by SBP reflects myocardial oxygen consumption. 
Thus, it plays an important role in cardiovascular 
risk stratification during exercise testing in pa-
tients with ischemic heart disease [15, 16]. There 
are many conflicting studies concerning the role of 
DP in cardiovascular risk stratification in healthy 
populations and hypertensive patients. According 
to some data, DP correlates positively with mortal-
ity in the general population [17]. However other 
authors discourage the use of DP as a cardiovas-
cular risk prediction determinant [18]. The impact 
of DP as well as other HR and BP products and 
ratios on prognoses in patients with CHF needs 
further study.
The aim of this prospective study was to 
evaluate the prognostic value of daytime HR, BP, 
their products and ratios in stable patients with 
CHF in providing useful, achievable tools in risk 
stratification.
Methods
There were 80 stable patients with CHF and 
HFrEF enrolled in this study. The inclusion criteria 
were as follows: age 18–80 years, stable clini-
cal status, CHF diagnosed at least 1 year before 
recruitment into the study, ischemic or dilated 
cardiomyopathy, LVEF ≤ 35% and optimal medical 
therapy. The exclusion criteria were as follows: 
CHF exacerbation within 3 months prior to the 
study, pregnancy and valvular heart disease as 
a cause of CHF. All patients recruited were dia-
gnosed and treated at the Cardiology Department 
according to the recent 2016 European Society of 
Cardiology (ESC) Guidelines for the diagnosis and 
treatment of acute HF and CHF [1]. All patients 
underwent following examinations: medical his-
tory, physical examination, laboratory tests, 12-lead 
resting electrocardiogram (ECG), chest X-ray, 
transthoracic echocardiography and the 6-minute 
walk test. Laboratory tests including the following 
parameters were assessed: total blood count with 
hemoglobin and red blood cell distribution width, 
sodium, potassium, urea, creatinine, glomerular 
filtration rate, total bilirubin, cholesterol, triglyc-
erides, uric acid, alanine transaminase, aspartate 
transaminase, glucose and B-type natriuretic 
peptide. 
Heart rate and BP obtained were mean day-
time values as determined through measurements 
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performed with 24-h telemetry monitoring and 
OMRON M7 Intelli IT device (Japan), 4 times 
a day, respectively. BP was measured at rest, 
each time twice with a 2 min pause at 6.00, 10.00, 
16.00 and 20.00 h. For analysis of median value all 
8 measurements was taken. Pulse pressure (PP) 
values were calculated as the difference between 
SBP and DBP.  The following products were also 
estimated and ratios: HR × SBP (DP), HR × DBP, 
HR × PP, HR/SBP, HR/DBP, HR/PP. The follow-
up period was 6 months. All follow-up data were 
obtained from visits or by telephone. MACE was 
defined as: death of all causes, cardiovascular death, 
hospitalization due to the HF exacerbation. The 
study protocol was approved by the Local Ethics 
Committee. 
Statistical analysis
All statistical calculations were performed 
using the statistical package StatSoft. Inc. (2014) 
STATISTICA (data analysis software system), ver-
sion 12.0. Quantitative variables were character-
ized by the arithmetic mean, standard deviation, 
median, minimum and maximum values (range) and 
95% confidence interval (CI). Whereas qualitative 
variables were presented using frequencies and 
percentages. To check whether a variable quantita-
tive came from a normally distributed population 
analysis using the Shapiro-Wilk. In contrast, test-
ing the hypothesis of equal variances test, Leven 
(Brown-Forsythe) was used. The significance of 
differences between the two groups (model vari-
ables unrelated) examined these test significance 
differences: Student t or, in the absence of homoge-
neity of variance, the Welch test or Mann-Whitney 
U (in cases of non-compliance with the conditions 
of applicability of the Student t test or for variables 
measured on the ordinal scale). Tests of independ-
ence c2 was used for categorical variables (by using 
Yates correction according to the number of cells 
below 10, checking conditions of Cochran and the 
Fisher exact test). In order to establish link strength 
and direction between variables, correlation analy-
sis was used in calculating the Pearson correlation 
coefficients and/or Spearman. In all calculations the 
level of significance was set at p = 0.05.
Results
Data of all 80 recruited patients were under 
analysis. The basic characteristics of the study 
population are presented in Tables 1 and 2. 
The mean age of the study group was 59 ± 
± 11 years and men constituted the majority of the 
population (91%). Most participants were in New 
York Heart Association (NYHA) II class (mean: 
2.2 ± 0.6). The majority of recruited subjects 
were nondiabetic (70%) and had CHF of ischemic 
origin (62.5%). Atrial fibrillation was confirmed 
in 22% of all study participants. For a majority of 
study population, comorbidities were reported. 
Three (4%) patients died during 3-month follow-
up, and 5 (6%) during a 6-month observation due 
to HF deterioration. Ten (12.7%) patients were 
subsequently hospitalized for CHF decompensa-
tion within 3-months and 19 (24%) during 6 month 
follow-up.
After a 3-month and excluding a 6 month ob-
servation period there was a significant correlation 
Table 1. Baseline characteristics of the study 
group. 
Variables Values
Age [year] 59 ± 12
Men 93 (91%)
BMI [kg/m2] 28.7 ± 5.4
NYHA class 2.15 ± 0.57
Heart rate [bpm] 75 ± 14.3
SBP [mmHg] 114 ± 14
DBP [mmHg] 70 ± 9.5
DP [bpm × mmHg] 8649 ± 1953.5
HR × DBP [bpm × mmHg] 5368 ± 1303.6
HR × PP [bpm × mmHg] 3272 ± 1066
HR/SBP [bpm/mmHg] 0.67 ± 0.15
HR/DBP [bpm/mmHg] 1.08 ± 0.24
HR/PP [bpm/mmHg] 1.94 ± 0.97
LVEF [%] 23.3 ± 6.7
6MWT distance [m] 351.3 ± 110.3
Ischemic CHF 50 (62.5%)
Prior MI 50 (62.5%)
Prior stroke 10 (12.5%)
Prior CABG 13 (16.25%)
Prior PCI 30 (37.5%)
Prior ICD 49 (61.25%)
Smoking 55 (68.75%)
Qualified to HTX 9 (11%)
BNP [pg/mL] 742 ± 701
Values are presented as means ± standard derivation or as number 
(percentages); BMI — body mass index; NYHA — New York Heart 
Association; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; DP —  double product; HR — heart rate; PP — pulse 
pressure; LVEF — left ventricular ejection fraction; 6MWT — six-
-minute walk test; CHF — chronic heart failure; MI — myocardial 
infarction; CABG — coronary artery bypass grafting; PCI — per-
cutaneous coronary interventions; ICD — impantable cardioverter 
defibrillator; HTX — heart transplantation; BNP — B-type natriuretic 
peptide
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between DBP and all-cause mortality (p = 0.048) 
as well as CHF decompensation (p = 0.0004) in 
the whole group. DBP was significantly higher in 
patients without CHF decompensation as well as 
in those who survived. No relationship was found 
between HR or SBP and MACE. Furthermore, it 
was observed that in patients with higher HR × 
× DBP product, risk of CHF decompensation was 
significantly lower in both 3-month (p = 0.001) 
and 6-month (p = 0.032) observation periods. 
Moreover, patients hospitalized for CHF exacerba-
tion in 6-month observation DP was significantly 
lower than in stable ones. No correlations were 
found between: DP, HR × DBP, HR × PP products 
and 3 or 6 month mortality. None of the following 
calculated quotients: HR/SBP, HR/DBP, HR/PP sig-
nificantly influenced the risk of CHF exacerbation 
or mortality. None of the presented factors were 
found to be significant for MACE risk stratification 
in multiple analysis of COX proportional hazard. 
The most significant correlations are presented 
in Tables 3 and 4.
Discussion
In this prospective study, it was demonstrated 
that daytime DBP may be a valuable risk stratifica-
tion factor for death and HF exacerbation in stable 
patients with CHF.  Within the present study popu-
lation mean SBP and DBP values were 114 ± 14 
mmHg and 70 ± 9.5 mmHg, respectively. It was 
shown that higher DBP but not SBP was associated 
with lower risk of death and CHF decompensation 
in the 3-month observation period. A relationship 
was not confirmed between DBP and MACE in the 
6-month observation period. It was presumed that 
this fact may be related to patient clinical status 
improvement during the follow-up period. Similar 
observations concerning DBP in HF have been 
reported in other previous studies. Lee et al. [5] 
in restrospective analysis of Digitalis Investigation 
Group (DIG) data revealed that in patients with 
systolic dysfunction (LVEF ≤ 45%) and NYHA II 
and III class, lower SBP and DBP were associated 
with greater mortality in short and long-term 
observation. This study supports the suggestion 
of other authors that patients with SBP < 110 
mmHg and DBP < 60 mmHg had a significantly 
higher risk of death. These observations have been 
documented in several studies. According to these 
authors, patients with SBP < 110 mmHg were 
at higher risk of mortality [19, 20]. The negative 
correlation between BP and mortality was also 
observed in a prospective study of patients with 
acute HF decompensation performed by Ghali et al. 
[21]. Lip et al. [22] A recent cohort study indicated 
that patients with incident HF and increased initial 
SBP and DBP values were at higher risk of adverse 
cardiovascular events. Similarly, Raphael et al. [6] 
revealed that contrary to the general population, 
higher SBP was a favourable prognostic marker 
in CHF which was not related to etiology, ACE 
inhibitor or beta-blocker use. Some authors have 
suggested that low daytime BP variability may 
also influence prognosis in patients with HF [23]. 
Sherazi et al. [24] and revealed that the absence of 
hypertension, as well as elevated urea and lower 
LVEF ≤ 45% indicate increased risk of short and 
long-term mortality. The relationship between 
DBP and MACE has been discussed in other publi-
cations concerning this subject [8, 25, 26]. McEvoy 
et al. [27] revealed an association between DBP 
< 60 mmHg and coronary heart disease events 
in Atherosclerosis Risk In Communities (ARIC) 
cohort study population. It has been documented 
that low DBP was related to subclinical myocardial 
damage and MACE. The most important conse-
Table 2. Comorbidities and medication use at 
baseline.
Variables Values
Hypertension 50 (62.5%)
Atrial fibrillation 16 (22%)
Diabetes mellitus 24 (30%)
Dyslipidemia 26 (32.5%)
COPD 17 (21.25%)
Liver dysfunction 9 (11.25%)
Renal dysfunction 16 (20%)
Thyroid dysfunction 11 (13.25%)
Peptic ulcer disease 7 (8.75%)
Peripheral arterial disease 5 (6.25%)
ASA 41 (51.25%)
Oral anticoagulatnts 9 (11%)
Beta-blockers 75 (93.75%)
Amiodarone 19 (23.75%)
Ivabradine 5 (6.25%)
Loop diuretics 75 (93.75%)
Aldosterone antagonists 12 (15%)
ACE inhibitors 70 (87.25%)
Statins 55 (68.75%)
ARB 10 (12.5%)
Digoxine 14 (17.5%)
Values are presented as numbers (percentages); COPD — chronic 
obstructive pulmonary disease; ASA — acetylsalicylic acid; ACE —  
angiotensin converting enzyme; ARB — angiotensin receptor 
blockers
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Table 3. Correlations between chosen variables and 3-month mortality rate.
Variable Survival (n = 77) Death (n = 3) P
HR
Mean (SD) 76.0 (14.0) 69.7 (24.6) 0.8792
Range 51.0–120.0 42.0–89.0
Median 75.0 78.0
95% CI [72.8;79.1] [8.6;130.7]
SBP
Mean (SD) 114.6 (14.7) 103.3 (9.5) 0.1795
Range 90.0–145.0 96.0–114.0
Median 110.0 100.0
95% CI [111.3;118.0] [79.9;126.8]
DBP
Mean (SD) 71.1 (9.4) 59.3 (9.0) 0.0482
Range 50.0–89.0 50.0–68.0
Median 70.0 60.0
95% CI [69.0;73.3] [36.9;81.7]
DP
Mean (SD) 8691.3 (1909.4) 7326.0 (3084.4) 0.5022
Range 5400.0–15600.0 4032.0–10146.0
Median 8280.0 7800.0
95%CI [8258.0;9124.7] [–336.2;14988.2]
HR × DBP
Mean (SD) 5410.5 (1269.6) 4277.3 (2006.5) 0.3488
Range 3000.0–9600.0 2100.0–6052.0
Median 5304.0 4680.0
95% ci [5122.4;5698.7] [–707.2;9261.8]
HR × PP
Mean (SD) 3280.8 (1071.5) 3048.7 (1082.8) 0.8296
Range 900.0–6300.0 1932.0–4094.0
Median 3000.0 3120.0
95% CI [3037.6;3524.0] [358.9;5738.4]
HR/SBP
Mean (SD) 0.68 (0.16) 0.67 (0.20) 0.7903
Mean (SD) 0.41–1.10 0.44–0.78
Range 0.66 0.78
Median [0.64;0.71] [0.17;1.16]
HR/DBP
Mean (SD) 1.09 (0.24) 1.15 (0.27) 0.5861
Range 0.64–1.83 0.84–1.31
Median 1.07 1.30
95% CI [1.03;1.14] [0.48;1.82]
HR/PP
Mean (SD) 1.95 (0.99) 1.60 (0.59) 0.6761
Range 0.98–8.08 0.91–1.95
Median 1.75 1.93
95% CI [1.73;2.18] [0.12;3.08]
SD — standard derivation; CI — confidence interval, other abbreviations — see Table 1
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Table 4. Correlations between chosen variables and 3-month chronic heart failure (CHF) exacerbations.
Variable No CHF decompensation (n = 61) CHF decompensation (n = 19) P
HR
Mean (SD) 76.5 (14.3) 69.2 (13.3) 0.2183
Range 51.0–120.0 42.0–89.0
Median 75.0 70.0
95% CI [73.0;79.9] [59.7;78.7]
SBP
Mean (SD) 115.3 (15.1) 107.0 (10.4) 0.1097
Range 90.0–145.0 96.0–130.0
Median 115.0 102.0
95% CI [111.7;118.9] [99.5;114.5]
DBP
Mean (SD) 72.1 (9.3) 60.7 (5.8) 0.0004
Range 50.0–89.0 50.0–70.0
Median 70.0 60.0
95% CI [69.8;74.3] [56.6;64.8]
DP
Mean (SD) 8796.7 (1947.2) 7434.2 (1694.1) 0.0525
Range 5400.0–15600.0 4032.0–10146.0
Median 8300.0 7 500.0
95% CI [8328.9;9264.4] [6222.3;8646.1]
HR × DBP
Mean (SD) 5511.7 (1265.1) 4229.7 (993.3) 0.0011
Range 3000.0–9600.0 2100.0–6052.0
Median 5394.0 4477.5
95% CI [5207.8;5 815.6] [3519.2;4940.2]
HR × PP
Mean (SD) 3285.0 (1107.7) 3204.5 (830.9) 0.9061
Range 900.0–6 300.0 1932.0–4779.0
Median 3000.0 3 000.0
95% CI [3018.9; 3551.1] [2610.1; 3798.9]
HR/SBP
Mean (SD) 0.68 (0.16) 0.65 (0.12) 0.8712
Range 0.41–1.10 0.44–0.78
Median 0.66 0.67
95% CI [0.64;0.72] [0.56;0.74]
HR/DBP
Mean (SD) 1.08 (0.25) 1.14 (0.21) 0.3925
Range 0.64–1.83 0.84–1.47
Median 1.07 1.17
95% CI [1.02;1.14] [0.99;1.29]
HR/PP
Mean (SD) 1.99 (1.03) 1.53 (0.37) 0.1548
Range 0.98–8.08 0.91–1.95
Median 1.75 1.51
95% CI [1.74;2.24] [1.26;1.80]
SD — standard derivation; CI — confidence interval, other abbreviations — see Table 1
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quence of DBP lowering is coronary blood flow 
reduction due to a lower perfusion gradient [27]. 
These mechanisms may be also present in patients 
with HF of ischemic origin. The present find-
ings support previous hypotheses that excessive 
hypotensive therapy in patients with HF leading 
to significant BP lowering may correlate with an 
increase in mortality rate. Some authors however, 
have not confirmed DBP association with mortality 
but only SBP with nonsudden cardiac death [7]. In 
contrast to our findings concerning the influence of 
DBP on CHF exacerbations, the most recent report 
by Voors et al. [28] noted an association between 
lower SBP but not DBP and hospitalizations owing 
to HF. Moreover, BP was not one of the strongest 
predictors of mortality due to HF. According to 
BARDICHE-index authors lower SBP was associated 
with higher HF exacerbation rate independently of 
LVEF [29]. Several authors have demonstrated that 
higher SBP was independently related to improved 
cardiovascular survival in patients with CHF [13, 21, 
24, 30]. Surprisingly, this study did not confirm the 
relationship between SBP and MACE in the whole 
group of patients or in study subgroups. Neverthe-
less, it should be underlined that in contrast to other 
studies only mean daytime values of SBP were taken 
into analysis. Furthermore, the examined group was 
small and observation period short. In the majority 
of studies examining this subject follow-up duration 
exceeded 1 year.
It has been documented that HR is an inde-
pendent risk factor in patients with HF. Elevated 
resting HR is associated with unfavourable pato-
mechanisms including: increased oxygen demand, 
diminuated ventricular relaxation and reduced 
stroke volume [31]. Many authors have revealed 
that HR reduction impacted favourably on out-
come in patients with HF [31–34]. According to 
the SHIFT study and substudy results, reduced 
HR was associated with relative risk reduction 
for cardiovascular death and/or HF worsening. 
Furthermore, lower HR was related to reversal 
of cardiac remodeling [14, 35]. A recent report 
by Zou et al. [36] noted that HR deceleration and 
acceleration capacities are independent risk fac-
tors for dilated cardiomyopathies. Moreover, HR 
acceleration may be a valuable HF exacerbation 
prognostic factor. Nevertheless, HR reduction in 
patients with chronic HFrEF is not associated with 
better survival in atrial fibrillation presence [37, 
38]. This study did not observe a significant cor-
relation between daytime HR and mortality or HF 
decompensation rate in short-term observation. 
It cannot be excluded, however, that prolonged 
observation and/or mean whole day HR values 
would have influenced the final results. Moreover, 
all patients were on optimal pharmacological treat-
ment affecting BP and HR.
In summary, according to many authors the 
prognostic role of BP and HR in HF outcome 
cannot be overestimated. Some authors have sug-
gested that combining HF and SBP constitutes 
a valuable prognostic factor in older patients with 
HF [39]. Nevertheless, there are still few reports 
concerning the prognostic value of HR and SBP 
combinations, products or quotients in patients 
with CHF. The results of the present study provide 
several new findings on this issue. It was found 
that higher HR × SBP product (DP) correlated 
negatively with CHF exacerbation risk in 6-month 
observation period. Similarly, patients with higher 
HR × DBP product were at lower risk of CHF 
decompensation both in 3-month and 6-month 
observation periods. The supposition was that 
those negative correlations are related to previ-
ously described reverse relationship between BP 
and HF outcome. No relationship was observed 
between: DP, HR × DBP, HR × PP products and 
mortality. There were no publications found which 
support the present observations. There were 
few conflicting studies examining the predictive 
role of DP in healthy or hypertensive populations 
[17, 18, 40]. Moreover, none of the calculated 
quotients impacted on MACE during follow up. 
No publications were found concerning this sub-
ject in patients with HF. There are some reports 
concerning the role of mean arterial pressure and 
heart rate quotient (PRQ) in myocardium hypop-
erfusion prediction. Buffington et al. [41] indicated 
that PRQ is an effective predictor of hypoperfusion 
of collateral-dependent myocardium. Mereu et al. 
[42] investigated HR/SBP quotient as predictor of 
neuromediated syncope. It has been revealed that 
HR/SBP ratio may be a valuable tool to estimate the 
occurence of syncope. Further studies are needed 
to estimate the prognostic role of combining HR 
and BP in populations with CHF. 
Limitation to the study
The prognostic value strength of proposed risk 
stratification factors may be diminuated by the fact 
that the majority of patients received pharmaco-
logical treatment including antihypertensive drugs 
(ACE inhibitors or ARB, diuretics, beta-blockers) 
and negative chronotropic agents (digoxin, beta-
blockers). Moreover, BP and HR values were not 
estimated by ambulatory BP monitoring but only 
through automatic several daytime BP measure-
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ments. However, the intention of this study was 
to verify the utility of simple BP measurements 
similar to those performed at home. Finally, the 
study population was small and the observation 
period short thus it may be difficult to extrapolate 
obtained results to general CHF populations.
Conclusions
This study revealed that DBP and DP, HR × 
× DBP products may be simple, achievable tools in 
the prediction of HF exacerbations in stable CHF 
patients in short-term observation. Moreover, 
a significant relationship was found between DBP 
value and 3-month mortality in this group of pa-
tients. None of the estimated products or quotients 
influenced mortality in the present study group.
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